S. 1095 · 119th Congress (2025–2027)
Stop STALLING Act
This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.
The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit is subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.
Show official title
A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.
Reported
This bill’s path
This is S. 1095’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed Senate
Passed House
Sent to President
Signed into law
- Sponsor
- Sen. Amy Klobuchar (D-MN)
- Cosponsors
6 cosponsors
6 original · 0 later
2 R · 4 D
- Sen. Richard Blumenthal (D-CT)· Original · Mar 24, 2025
- Sen. Cory A. Booker (D-NJ)· Original · Mar 24, 2025
- Sen. Ted Cruz (R-TX)· Original · Mar 24, 2025
- Sen. Richard J. Durbin (D-IL)· Original · Mar 24, 2025
- Sen. Chuck Grassley (R-IA)· Original · Mar 24, 2025
- Sen. Peter Welch (D-VT)· Original · Mar 24, 2025
- Policy area
- Health
- Subjects
- Administrative remedies
- Business ethics
- Civil actions and liability
- Competition and antitrust
- Department of Health and Human Services
- Drug safety, medical device, and laboratory regulation
- Food and Drug Administration (FDA)
- Licensing and registrations
2 more
- Prescription drugs
- Public participation and lobbying
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in Senate
Document: Introduced in Senate
Sources
- Congress.gov action
- Library of Congress
- Latest
▸ 3 committee actions · Mar 24, 2025 – Apr 10, 2025
Referred to committee
Read twice and referred to the Committee on the Judiciary.
Sources
- Congress.gov action
- Senate
Ordered reported
Committee on the Judiciary. Ordered to be reported without amendment favorably.
Sources
- Congress.gov action
- Senate
Reported by committee
Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.
Sources
- Congress.gov action
- Senate
Committees
Apr 3, 2025 · Meeting
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
Titles (3)
Stop STALLING Act
Short title, Display title · Reported to Senate, Introduced in Senate
Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act
Short title · Reported to Senate, Introduced in Senate
A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes.
Official title · Introduced in Senate